MarketPeel
LL

Lorena Raquel Lerner

KROS
CHIEF SCIENTIFIC OFFICER · KEROS THERAPEUTICS, INC. · CIK 0002081359
FILING MIX · LIFETIME33%/67%
BUYS
1
SELLS
2
TOTAL VALUE
$100.0K
COMPANIES
1
ACTIVE SINCE
Feb 2026
HOLDINGS NOW
27,559
AVG SELL PX
$13.44
TRADE KIND
SHOWING 3 / 3
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 2 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Lorena Raquel Lerner, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%-5.88%+1.00%-6.88%-6.88%
14d1+100.00%-14.84%-0.17%-14.67%-14.67%
30d1+100.00%-32.22%-5.50%-26.72%-26.72%
60d1+100.00%-27.89%+3.27%-31.16%-31.16%
90d1+100.00%-38.71%+8.16%-46.88%-46.88%
180d1+100.00%-37.54%+13.12%-50.66%-50.66%
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KROS · 27,559 shares · as of Aug 18, 2026
018,75037,50056,25075,000SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2026
2026
2026
FLOW · 1 buys / 2 sellsCOVERAGE · 3 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KROS
KEROS THERAPEUTICS, INC.
SALE
Chief Scientific Officer
3,568$10.29$36.7K27,559Aug 18, 2026Aug 20, 2026View →
KROS
KEROS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
75,00075,000Feb 24, 2026Feb 26, 2026View →
KROS
KEROS THERAPEUTICS, INC.
SALE
Chief Science Officer
3,873$16.35$63.3K31,127Feb 18, 2026Feb 20, 2026View →
Other insiders · KROS
Loading peer insiders…
About this filer
CIK 0002081359
ROLE
Chief Scientific Officer
PRIMARY
KROS
COMPANIES
1
ACTIVE SINCE
Feb 2026
MARKETPEEL · /INSIDER/0002081359DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback